ANTX

Eric Easom

Known title: Chief Executive OfficerCIK: 0001914503

Eric Easom's purchase track record

How the stock did after each of Eric Easom's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 3 since May 15, 2023
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+19.0%
3 months: +14.0%
Beat the S&P 500
67%
median +17.8% vs. index
PurchaseStockAmount3 months6 months
6/2/2025ANTX$11K+8.5%-0.9%
11/18/2024ANTX$50K+14.0%+19.0%
5/15/2023ANTX$54K+54.9%+175.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 27, 2026

AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.

this person other insiders at ANTX

Transaction History

ANTX▲ Buy$0
ANTX▲ Buy$11K
ANTX▲ Buy$0
ANTX▲ Buy$50K
ANTX▲ Buy$0
ANTX▼ Sell$56K
ANTX▲ Buy$54K
ANTX▼ Sell$346
ANTX▼ Sell$68K
ANTX▼ Sell$158K
ANTX▼ Sell$89K
ANTX▼ Sell$21K
ANTX▼ Sell$162K
ANTX▼ Sell$34K
ANTX▼ Sell$139K
ANTX▼ Sell$174K
ANTX▼ Sell$49K
ANTX▼ Sell$23K
ANTX▼ Sell$41K
ANTX▼ Sell$25K
ANTX▼ Sell$14K
ANTX▼ Sell$25K
ANTX▼ Sell$9K
ANTX▼ Sell$67K
ANTX▼ Sell$46K
ANTX▼ Sell$189K
ANTX▼ Sell$39K
ANTX▼ Sell$121K
ANTX▼ Sell$532
ANTX▼ Sell—

We use analytics to understand how market-wall is used. No personal data is sold.